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1. Introduction
Schizophrenia is a common, severe mental 
disorder of unknown etiology. It usually 
appears during adolescence and early 
adulthood and is characterized by positive 
and negative symptoms that reflect disruption 
of thought, mood, perception, and volition. 
Neurobehavioral fMRI studies have shown 
that impaired attention, working memory 
and decision-making (as functions of the 
dorsolateral prefrontal cortex, DLPFC), and 
impaired sensory integration, affect regulation 
and emotion processing, social cognition and 
metacognition (as functions of the medial 
orbitofrontal cortex, MOFC), are core features of 
schizophrenia [1, 2]. Whereas the concordance 
for schizophrenia in identical twins is about 
48%, the incidence decreases with decreased 
level of genetic similarity to about 6-17% in 
first-degree relatives, 2-6% in second-degree 
relatives, and 1-2% in third-degree relatives 
and the general population [3]. The earlier 
mentioned domains of cognitive function 
appear to be mildly impaired in the unaffected 
relatives of individuals with schizophrenia, 
which indicates that cognitive dysfunction 
likely reflects the genetic liability for the illness 
[4]. 
Some of the main candidate genes for 
genetic susceptibility for schizophrenia are 
DISC1 (disrupted in schizophrenia 1), DTNBP1 
(dystrobrevin binding protein 1), RGS4 
(regulator of G-protein signaling 4), PRODH 
(proline dehydrogenase), NRG1 (neuroregulin 
1), COMT (catechol-O-methyl transferase), but 
many others have been reported (e.g., TRAR4, 
GABAA, PIP5K2A, ZDHHC8, G72/G30, CAPON, 
SYN2, GRM3, CHI3L1, SPEC2/PDZ-GEF2/ACSL6, 
FXYD6, PPP3CC) [5, 6]. In addition, a recent large 
genome-wide association study identified 108 
schizophrenia-associated loci, out of which 83 
were previously not reported [7]. 
The main goal of this study was to assess 
whether gene expression patterns differ 
between normal control and schizophrenic 
brain in regions of the prefrontal cortex 
implicated in schizophrenia etiology and 
symptomatology. Although psychosis 
(hallucinations, delusions, and disorganized 
behavior) is the most pronounced clinical 
feature of schizophrenia, impaired cognition 
has been suggested to be a core domain of 
dysfunction [8]. Therefore, we analyzed gene 
expression in the dorsolateral prefrontal 
cortex (DLPFC, Brodmann’s area 46) and in the 
medial orbitofrontal cortex (MOFC, Brodmann’s 
area 11/12) of subjects with schizophrenia 
and normal controls. DLPFC was selected 
primarily because impaired working memory 
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is a hallmark endophenotype of schizophrenia 
[9], and because working memory deficits 
are among the key cognitive impairments of 
schizophrenia that remain relatively stable 
despite fluctuations in symptoms over the 
course of the disease [10]. MOFC has been 
proposed to be involved in sensory integration, 
in representing the affective value of reinforcers, 
in decision-making and expectation, as well 
as intuitive coherence judgments, subjective 
control of action and believing [11]. Imaging 
studies have confirmed that the activity in the 
left orbitofrontal region (area 11) is impaired in 
schizophrenic patients. Together with several 
other regions, the left area 11 is critically 
associated with directed efforts (i.e., realizing 
control of internal thoughts) such as the ability 
to represent, monitor and control the thoughts, 
feelings, and actions of self (a process called 
metacognition) [12], and of others across time 
(mentalization) [13]. As the aberrant activity 
and connectivity of the left MOFC may reflect 
impairments in the perception and initiation of 
action and be responsible for both the positive 
and negative symptoms of schizophrenia, we 
additionally tested whether the difference 
in gene expression observed between the 
left and the right hemispheres also differed 
between schizophrenic and control brains. The 
level of gene expression in these areas of the 
brain could offer valuable insight into the cause 
of symptoms seen in schizophrenia as well as 
its etiology.
2. Materials and methods
2.1. Study samples
Postmortem samples of DLPFC and MOFC were 
obtained from 6 brains from subjects with 
schizophrenia and 6 normal controls from the 
Zagreb Collection of human brains [14]. The 
normal control subjects were chosen to match 
the schizophrenic group closely for age and 
postmortem delay (Table 1). All schizophrenic 
patients met the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, 
American Psychiatric Association, 2000 (DSM-
IV-TR) [15] diagnostic criteria for schizophrenia 
and were, until their death, under long-term 
treatment (with either clozapine, olanzapine, or 
risperidone), and had regular clinical follow-ups 
by at least one experienced psychiatrist. Both 
the schizophrenic subjects and controls were 
carefully chosen so that the brains selected 
for analysis were not taken from subjects who 
had a prior history of head trauma, alcohol or 
drug abuse, or other major neuropsychiatric 
disorders.
2.2. Dissection of tissue samples
Gray matter tissue samples were carefully 
dissected from the mid frontal (area 46) 
and orbitofrontal (area 11/12) regions, 
which correspond to DLPFC and MOFC, 
respectively (Figure 1) [16-18]. Each sample 
had an approximate volume of about 0.5 
cm3. The caudal part of each block was 
used for staining with cresyl-violet (Nissl 
stain). The Nissl stain served to check for the 
cytoarchitectural features of the Brodmann’s 
areas analyzed. Area 46 was identified by 
the criteria described in Rajkowska et al. 
1995 [19]. Area 46 is bounded dorsally by 
the granular frontal area 9, rostroventrally by 
the frontopolar area 10, and caudally it joins 
the triangular area 45 (16, 17, 19). Area 11 is 
bordered on the rostral and lateral aspects of 
the hemisphere by the frontopolar area 10, 
the orbital area 47, and the triangular area 
45; on the caudal aspect it abuts subgenual 
area 25. On the medial surface it continues 
into rostral area 12.
2.3. RNA extraction, purification and 
quality control
After dissection, the samples were immediately 
placed in the RNAlater solution (Thermo Fischer 
Scientific, Waltham, MA, USA), in which RNA 
was stabilized, and then stored in the freezer at 
-80°C until further analysis. For each microarray 
analysis, we used 20-30 mg of brain tissue from 
either area 46 or area 11/12. Isolation of RNA 
from brain tissue samples was performed using 
RNeasy Plus Mini kit from Qiagen (Venlo, The 
Netherlands) according to the manufacturer’s 
protocol. Concentrations and quality of isolated 
RNA were measured by using Bioanalyzer 2100 
and RNA 6000 Nanochip Kit (both from Agilent, 
Palo Alto, CA, USA). RNA degradation was 
assessed by quantifying the resulting 28S/18S 
ribosomal band peak height ratios: all samples 
were in the acceptable range of values between 
1.5 and 2.0. The quality of each sample was 
further assured by a RNA integrity number 
(RIN) greater than 5 (Table 1). Only 2 out of 48 
samples had RIN value smaller than 5, and were 
discarded from the analysis. 
Table 1. Demographic and tissue characteristics of the schizophrenia (SZ) and normal control (NC) brain samples 
analyzed. PMD, postmortem delay; RIN, RNA integrity number; SD, standard deviation. RIN was calculated using 
a proprietary algorithm of the Agilent Technologies, Santa Clara, CA, USA.
Subject Code Gender Age (years) PMD (h) RIN Cause of death
SZ group
SZ1 M 59 26 8.65 ± 0.17 Suicide by hanging
SZ2 F 56 20 7.40 ± 0.56 Pneumonia
SZ3 F 57 6 4.93 ± 0.50 Sudden cardiac arrest
SZ4 M 50 14 8.13 ± 0.22 Heart failure
SZ5 F 47 24 8.03 ± 0.26 Sudden cardiac arrest
SZ6 F 42 24 4.98 ± 0.43 Drug poisoning
Mean ± SD 51.83 ± 6.62 19 ± 7.67 7.02 ± 1.65
NC group
NC1 M 54 17 7.53 ± 0.36 Heart failure
NC2 F 60 6 6.90 ± 0.71 Sudden cardiac arrest
NC2 F 61 24 8.55 ± 0.64 Heart failure
NC4 F 40 30 7.65 ± 0.37 Heart failure
NC5 M 55 13 8.55 ± 0.21 Heart failure
NC6 M 42 24 8.75 ± 0.07 Heart failure
Mean ± SD 52.00 ± 8.97 19 ± 8.72 7.99 ± 0.74
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2.4. Microarray procedure
Total RNA was reverse-transcribed and 
hybridized onto Affymetrix HG-U133 Plus 
2.0 array, using the identical protocol and ID 
names for genes as GeneChip Human Exon 
1.0ST Arrays (Affymetrix, Santa Clara, CA, USA). 
The Affymetrix Human Gene Chip Exon 1.0 
ST Array interrogates over one million exons 
representing over 17,868 NCBI Reference 
Sequence (RefSeq) transcripts. Arrays were run 
using the manufacturer’s technical protocol 
(Affymetrix, Santa Clara, CA). Briefly, 2 μg 
of total RNA was subjected to a ribosomal 
RNA removal procedure (RiboMinus Human/
Mouse Transcriptome Isolation Kit, Invitrogen 
– Thermo Fischer Scientific) to reduce the 
28S and 18S rRNA population to minimize 
background and increase sensitivity of the 
assay. Reduced RNA was reverse-transcribed 
to cDNA using random hexamers tagged with 
a T7 promoter sequence followed by a second 
strand cDNA synthesis using DNA polymerase 
(GeneChip WT cDNA Synthesis Kit, Affymetrix). 
The resulting double-stranded cDNA was used 
for amplification of antisense cRNA and cleaned 
using the Gene Chip Sample Cleanup Module 
(Affymetrix). A second cycle cDNA synthesis 
was performed using random primers to 
reverse transcribe the cRNA into sense single 
stranded DNA, which was fragmented, labeled, 
and hybridized to arrays. Arrays were washed, 
stained, and scanned on the Affymetrix Fluidics 
Station and G7 Affymetrix high-resolution 
scanner using GCOS 1.3.
2.5. Microarray data preparation and 
analysis
The resulting gene expression values were 
derived from the microarray scan data (.cel 
files) and analyzed by using Partek Genomic 
Suite software ver. 6.5 (Partek Incorporated, 
St. Louis, MO, USA). Data preparation included 
corrections for background signal noise 
made by a robust multi-array average (RMA) 
procedure, as described in Irizarry et al. [20], 
and log2 transformation of yielded fluorescence 
intensities. After quantile normalization of the 
data and the averaging of probe signals by 
the arithmetic mean, the average expression 
values were calculated for each sample group 
and those showing a fold change of less than 
1.5 were omitted, followed by removal of those 
with a p-value greater than 0.05. It is possible 
that these subjective filtering criteria resulted in 
some genuinely differentially expressed genes 
being omitted from the final analysis. As such 
we provide the raw data as a supplementary file 
to allow for reanalysing of the data with other 
approaches (Appendix A. Supplementary data). 
Schizophrenia and normal control groups 
were compared on mean expression levels 
of all transcripts using Student’s t test, with a 
significance level of p < 0.05. To gain insight 
into the likely functions of the differentially 
expressed genes, gene ontology analysis was 
performed using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) 
[21, 22]. Functional annotations that were 
assigned with a p-value higher than 0.05 
were eliminated, followed by elimination of 
redundant terms.
3. Results
3.1. Differentially expressed genes
After applying the filtering criteria described 
in the Materials and Methods, five genes were 
found to be differentially expressed with 
statistical significance when the DLPFC from 
patients with schizophrenia (left and right 
hemispheres combined) was compared to the 
DLPFC from healthy controls (Table 2). Of these, 
one, TARDBP, had increased expression in the 
schizophrenic DLPFC compared to controls, 
while the remaining four genes had decreased 
expression. Comparison of the schizophrenic 
MOFC (left and right combined) to the MOFC 
from controls also identified five genes 
that were differentially expressed (Table 2), 
although only two of these (TARDBP and KRT18) 
were also detected in the DLPFC comparison.
By separating the data and analyzing them 
according to which hemisphere the tissue was 
Figure 1. Locations of dissected samples. Both areas are labeled in transparent red color. A. Area 46, which corresponds to dorsolateral prefrontal cortex (DLPFC), B. Area 
11/12 corresponds to medial orbitofrontal cortex (MOFC). See text for details.
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sampled from, we observed some differences 
compared to the analysis of the values from both 
hemispheres combined. Comparison of the left 
schizophrenic DLPFC to the left control DLPFC 
identified 18 genes that were differentially 
expressed with statistical significance, while 
comparison of the right DLPFC did not detect 
any genes that met the criteria for inclusion 
(Table 3 and Fig. 2). Similarly, 14 genes 
were differentially expressed when the left 
schizophrenic MOFC was compared to controls, 
and only one gene was differentially expressed 
in the right schizophrenic MOFC (Table 4 and 
Fig. 2). For the purpose of these comparisons, 
genes detected as repeated hits with separate 
identifiers (e.g., SEPT2 and GDI2; Table 3) were 
each counted separately because they most 
probably account for different splice variants. 
It is possible, however, that duplicate hits arose 
due to the presence of a palindromic sequence.
3.2. Gene ontology analysis
To gain insight into the possible functions 
of the differentially expressed genes in 
Tables 2 and 3, we performed gene ontology 
analysis using the Database for Annotation, 
Visualization and Integrated Discovery 
(DAVID) tool [21, 22]. Functional annotations 
that were assigned with a p-value higher than 
0.05 were eliminated, followed by elimination 
of redundant terms. Several biological 
process terms were enriched among the list 
of differentially expressed genes and these 
are summarized in Figure 3. In addition, the 
molecular function term “RNA binding” was 
assigned to six of the genes.
Table 2. Differences in gene expression for DLPFC (area 46) and MOFC (area 11/12) between schizophrenia (SZ) and control (NC) group.
Gene name Identifier Average 
expression 
change in SZ 
Significance
(P values)
Name and function(s)
SZ vs NC: DLPFC and MOFC together from both hemispheres
KRT18 4028716 -1.67 0.000512*** Keratin 18; intermediate filament
involved in poly(A) RNA binding, scaffold protein binding and 
filament reorganization
XGY2 4028512 -1.64 0.000028**** XG pseudogene on Y chromosome; function unknown
DDX3Y 4030162 -1.45 0.000081**** RNA helicase on Y chromosome; involved in RNA splicing, cell cycle, apoptosis and 
differentiation
TTTY15 4030063 -1.43 0.000431*** Testis-specific transcript on Y chromosome; non-coding RNA, function unknown
TARDBP 2320116 1.52 0.000062**** Transactive response DNA binding protein; bind both DNA and RNA and have multiple 
functions in transcriptional repression (e.g. represses HIV-1 transcription), pre-mRNA splicing 
and translational regulation; hyperphosphorylated, ubiquinated and cleaved form (TDP-43 
protein) is the major disease protein in FTLD-TDP and ALS.  
SZ vs NC: DLPFC from both hemispheres
KRT18 4028716 -1.69 0.012059* Keratin 18; intermediate filament
involved in poly(A) RNA binding, scaffold protein binding and 
filament reorganization
XGY2 4028512 -1.63 0.003009** XG pseudogene on Y chromosome; function unknown
DDX3Y 4030162 -1.52 0.006221** RNA helicase on Y chromosome; involved in RNA splicing, cell cycle, apoptosis and 
differentiation
TTTY15 4030063 -1.47 0.011882* Testis-specific transcript on Y chromosome; non-coding RNA, function unknown
TARDBP 2320116 1.51 0.002267** Transactive response DNA binding protein; bind both DNA and RNA and have multiple 
functions in transcriptional repression (e.g. represses HIV-1 transcription), pre-mRNA splicing 
and translational regulation; hyperphosphorylated, ubiquinated and cleaved form (TDP-43 
protein) is the major disease protein in FTLD-TDP and ALS.  
SZ vs NC: MOFC from both hemispheres
XGY2 4028512 -1.64 0.005236** XG pseudogene on Y chromosome; function unknown
KRT18 4028716 -1.64 0.022923* Keratin 18; intermediate filament
involved in poly(A) RNA binding, scaffold protein binding and 
filament reorganization
unconfirmed 3275188 1.51 0.001394** Probably a non-protein coding RNA
TARDBP 2320116 1.52 0.011170* Transactive response DNA binding protein; bind both DNA and RNA and have multiple 
functions in transcriptional repression (e.g. represses HIV-1 transcription), pre-mRNA splicing 
and translational regulation; hyperphosphorylated, ubiquinated and cleaved form (TDP-43 
protein) is the major disease protein in FTLD-TDP and ALS.  
SNX3 2968446 1.55 0.006198** Sorting nexin 3 protein; involved in endosome trafficking; interacts with PtdIns3P
Table legend: ALS, amyotrophic lateral sclerosis; FTLD-TDP, frontotemporal lobar degeneration due to TDP-43-positive neuronal inclusions; HIV1, human immunodeficiency 
virus 1; PtdIns3P, phophatidylinositol 3-phosphate; TDP-43, transactive response DNA protein of 43 kDa; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. 
Translational Neuroscience
Brought to you by | Keele University
Authenticated
Download Date | 1/26/17 4:13 PM
143
3.3. Interhemispheric transcriptome 
differences 
Furthermore, to assess possible asymmetric 
gene expression between the left and right 
hemispheres, we performed an expression 
analysis between the right and left hemispheres 
of control brains, and between the two 
hemispheres within the schizophrenia samples. 
The only difference we found was in the DLPFC 
of normal subjects, that showed a reduced 
expression of KAT7 gene in the left hemisphere 
by 41% (p = 0.014), an increased expression of 
gene NONO in the left hemisphere by 52% (p 
= 0.005).
Other genes that were detected to have 
significantly different expression among 
the schizophrenia and control cases were 
catalogued for the left hemisphere DLPFC 
(Table 3) and left hemisphere MOFC (Table 4).
4. Discussion
Our transcriptomic study brings new 
knowledge about gene expression differences 
between areas 46 and 11/12 from the left and 
right hemispheres of schizophrenic and control 
brains. Our results only partially overlap with 
the results of other gene expression studies, 
probably due to the analysis of RNA from 
different tissues and brain regions [23-33]. For 
the majority of differentially expressed genes 
between schizophrenia and control samples 
in the left hemisphere, an association with 
schizophrenia has already been reported. 
Particularly strong evidence exists for TARDBP 
and HNRNPC [34-36], followed by CANX 
Table 3. Differences in gene expression in the dorsolateral prefrontal cortex (DLPFC, area 46) between schizophrenia (SZ) and control (NC) brains.
Gene name Identifier Average 
expression change 
in SZ 
Significance
(P value)
Name and function(s)
SZ vs NC: DLPFC (area 46) left side only
KRT18 4028716 -1.81 0.040313* Keratin 18; intermediate filament
involved in poly(A) RNA binding, scaffold protein binding and 
filament reorganization; its promotor is responsive to EGFR activation
XGY2 4028512 -1.75 0.007113** XG pseudogene on Y chromosome; function unknown
DDX3Y 4030162 -1.68 0.010251* RNA helicase on Y chromosome; involved in RNA splicing, cell cycle, apoptosis and 
differentiation
TTTY15 4030063 -1.55 0.024267* Testis-specific transcript on Y chromosome; non-coding RNA, function unknown 
RPS13 3364736 -1.51 0.006037** Ribosomal protein S13; involved in poly(A) RNA binding and mRNA binding
ACTA2 3299504 -1.50 0.012868* Actin α2; recently described mutations support the role in development of frontal lobe, 
cingulate gyrus, corpus callosum and cerebellum 
KAT7 3725964 1.49 0.005552** Lysine acetyltransferase 7; forms histone acetyltransferase (HAT) complex 
USP22 3749728 1.49 0.001972** Ubiquitin-specific peptidase 22; a histone deubiquitinating component of the transcription 
regulatory HAT complexes, such as SAGA (Spt/Ada/Gcn5L acetyltransferase)
GDI2# 3275374 1.50 0.011052* GDP dissociation inhibitor 2; involved in vesicular trafficking of molecules between cellular 
organelles and G-protein coupled receptors (GPCR) signalling (such as dopamine receptors)
SEPT2# 2536335 1.51 0.000687*** Septin 2; involved in GTP binding and ERK signalling; may also play a role in the internalization 
of intracellular microbial pathogens (e.g. Listeria monocytogenes and Shigella flexneri)
SEPT2# 2536333 1.51 0.002780** Septin 2; involved in GTP binding and EGFR signalling; may also play a role in the 
internalization of intracellular microbial pathogens
NPM1# 2840668 1.51 0.002012** Nucleophosmin; involved in ribosome biogenesis, protein chaperoning, histone assembly and 
many other functions with multiple binding partners
SNX3 2968446 1.52 0.001712** Sorting nexin 3 protein; involved in endosome trafficking and interacts with PtdIns3P
NPM1# 2840726 1.54 0.011123* Nucleophosmin; involved in ribosome biogenesis, protein chaperoning, histone assembly and 
many other functions with multiple binding partners
GDI2* 3275252 1.54 0.017255* GDP dissociation inhibitor 2; involved in vesicular trafficking of molecules between cellular 
organelles and G-protein coupled receptors (GPCR) signaling (such as dopamine receptors)
unconfirmed 3275254 1.59 0.002173** Probably a non-protein coding RNA
unconfirmed 3275188 1.63 0.002547** Probably a non-protein coding RNA
TARDBP 2320116 1.73 0.006721** Transactive response DNA binding protein; bind both DNA and RNA and have multiple 
functions in transcriptional repression (e.g. represses HIV-1 transcription), pre-mRNA splicing 
and translational regulation; hyperphosphorylated, ubiquinated and cleaved form (TDP-43 
protein) is the major disease protein in FTLD-TDP and ALS.  
SZ vs NC: DLPFC (area 46) right side only
No significant changes with a 1.5 fold expression level cut-off
Table legend: EGFR, epidermal growth factor receptor; FTLD-TDP, frontotemporal lobar degeneration due to TDP-43-positive neuronal inclusions; GDP, guanosine diphos-
phate; GTP, guanosine triphosphate; TDP-43, transactive response DNA protein of 43 kDa; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. Genes marked with # are different 
splicing variants of the same gene.
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positive pathology exhibit schizophrenia-like 
psychosis [49]. 
The decreased expression of RPS13 
(encoding the ribosomal protein S13) in 
DLPFC of schizophrenic brains is of particular 
interest, considering that the RPS13 gene falls 
within the region around the novel single 
nucleotide polymorphism (SNP) associated 
with schizophrenia [43]. In contrast, an 
increased expression of RPS13 was recently 
the schizophrenia brains. Among them, the 
translational regulator and repressor, TARDBP 
(TAR DNA binding protein, also known as 
TDP-43), was increased in expression in the 
left hemisphere of DLPFC from schizophrenic 
brains. Abnormal nuclear expression of TARDBP 
in the hippocampus of patients with late-onset 
psychosis and familial history of psychiatric 
illness was previously reported [35, 36], and 
patients with young-onset FTD and TARDBP-
[37], SNX3 [38], GDI2 [39], and SLC25A3 [40]. 
Association of CBX3 [41], DDX3Y, USP22 [42], 
RPS13 [43], STARD7 [44], ACTA2 [45], and 
KRT18 [46] with schizophrenia was reported 
in few studies, while SART1, KAT7, C1D, NPM1, 
EVI2A, XGY2, and TTTY15 genes were not 
previously related to schizophrenia. In the 
right hemisphere, only CANX showed a higher 
expression in the MOFC of subjects with 
schizophrenia, while no gene in the DLPFC had 
a difference in expression.
4.1. Genes associated with RNA 
processing 
The subfamily of heterogeneous nuclear 
ribonucleoproteins (hnRNPs) forms complexes 
with heterogeneous nuclear RNA and influence 
pre-mRNA processing, and mRNA transport and 
metabolism. Here, we identified an increased 
expression of HNRNPC (heterogeneous nuclear 
ribonucleoprotein C (C1/C2)) in MOFC of 
schizophrenic brains, along with an increased 
expression of the gene encoding the hnRNPC-
interacting protein, SART1 (squamous cell 
carcinoma antigen recognized by T-cells 1) 
[47]. Cohen et al. [25] also reported increased 
expression of HNRNPC, along with two other 
hnRNPs, HNRNPH1 and HNRNPH3, in area 10 
of schizophrenic brains, although they did not 
precise whether their samples were derived 
from the left, right, or both hemispheres. 
Similarly, Föcking et al. identified increased 
levels of HNRNPC protein in the postsynaptic 
density of supragenual anterior cingulate 
cortex (area 24) of schizophrenic brains, and 
implicated other members of the hnRNP 
subfamily such as HNRNPA3, HNRNPK, and 
HNRNPU in the pathogenesis of schizophrenia 
[34]. One of the functional consequences of 
HNRNPC dysregulation might involve myelin-
related processes since HNRNPC regulates the 
expression of myelination-related genes MBP, 
QKI-5, QKI-6 and QKI-7 [48]. This finding is in line 
with numerous evidences about involvement 
of oligodendrocytes in the pathology of 
schizophrenia at the histological [27, 49-52] 
and gene expression level [52]. 
Further support for this concept arises 
from our gene ontology analysis, suggesting 
that five additional genes involved in RNA 
processing or splicing were dysregulated in 
Figure 3. Schematic representation of the number of differentially expressed genes with respect to gene ontol-
ogy terms.
Figure 2. Representation of a number of differentially expressed genes between schizophrenia and normal con-
trol brains using Venn diagram. DLPFC, dorsolateral prefrontal cortex, MOFC, medial orbitofrontal cortex. Genes 
marked with asterisk are different splicing variants of the same gene.
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reported in olfactory cells derived from 
schizophrenia patients [53]. It will be of interest 
to determine whether differences in gene and 
protein expression between cell types and 
brain regions may help to explain the region-
specific pathophysiological symptoms in 
schizophrenia. 
C1D and NPM1 were also differentially 
expressed genes with RNA-associated functions. 
NPM1, an ARF/p53 pathway regulator, showed 
increased expression in orbitofrontal cortex 
of schizophrenic brains and was identified 
as part of schizophrenia-associated protein 
network [35, 36]. C1D has apoptotic-inducing 
activity and was previously not correlated 
to schizophrenia in other studies. As there is 
a dysregulation of genes coding for similar 
functions in multiple studies, perturbation of 
RNA splicing proteins may play a causative role 
in the well-characterized decreased working 
memory function, attributed to the DLPFC and 
area 10, in the schizophrenic brain [54].
4.2. Genes associated with dendritic 
spine structure
It has been shown that genetic aberrations 
that affect the regulation and dynamics 
of actin filaments could be involved in the 
pathophysiology of schizophrenia by disrupting 
dendritic spine architecture and glutamatergic 
signaling (for review see [8]). Cohen et al. 
[25] found that the ENAH gene, which codes 
for actin-related cytoskeleton remodeling 
and the CPNE3 gene, which codes for actin-
binding domains, have decreased expression 
in area 10 in subjects with schizophrenia. Our 
findings that ACTA2 gene, which codes for 
actin α2, has a decreased expression, whereas 
SEPT2, which assists in actin cytoskeleton 
formation, is overexpressed in the left 
DLPFC in schizophrenia (other members of 
septin family have also been associated with 
schizophrenia: SEPT4, SEPT5, SEPT8, and SEPT11 
[39]), fit well to these reports. As both genes are 
associated with dendritic spine structure and 
Table 4. Differences in gene expression in the MOFC (area 11/12) between schizophrenia (SZ) and control (NC) brains.
Gene name Identifier Average expression 
change in SZ 
Significance
(P value) Name and function(s)
SZ vs NC: MOFC (area 11/12) left side only
GDI2# 3275388 1.76 0.000033**** GDP dissociation inhibitor 2; involved in vesicular trafficking of molecules between 
cellular organelles and G-protein coupled receptors (GPCR) signaling (such as dopamine 
receptors)
CBX3 2993696 1.52 0.000032**** Chromobox protein homolog 3; a heterochromatin protein that can bind DNA and 
lamin; it is recruited to sites of DNA damage and binds to histone H3 tails (thus can be 
involved in transcriptional reprogramming)
SNX3 2968446 1.62 0.000893*** Sorting nexin 3 protein; involved in endosome trafficking and interacts with PtdIns3P
SART1 3335846 1.64 0.001175** Squamous cell carcinoma antigen recognized by T-cells 1; protein involved in RNA 
splicing and pre-mRNA processing
STARD7 2565180 1.63 0.009539** StAR-related lipid transfer domain protein 7; lipid transporter that specifically bind and 
transports phosphatidylcholine between membranes
GDI2# 3275252 1.58 0.002656** GDP dissociation inhibitor 2; involved in vesicular trafficking of molecules between 
cellular organelles and G-protein coupled receptors (GPCR) signaling (such as dopamine 
receptors)
SLC25A3 3427855 1.53 0.003733** Solute carrier family 25 member 3; catalyzes the transport of phosphate into the 
mitochondrial matrix  
ANAPC5 3475146 1.51 0.003543** Anaphase promoting complex subunit 5; a large E3 ubiquitin ligase required for the 
proper ubiquitination; also controls cell cycle progression and interacts with poly (A) 
binding protein and represses internal ribosome entry site-mediated translation
HNRNPC 3556086 1.50 0.002927** Heterogeneous nuclear ribonucleoprotein C; involved in pre-mRNA processing, mRNA 
transport and metabolism
C1D 2557627 1.59 0.013190* Nuclear nucleic acid-binding protein C1D; apoptosis-inducing and DNA binding protein 
XGY2 4028512          -1.58 0.031729* XG pseudogene on Y chromosome; function unknown
unconfirmed 3275188 1.57 0.012645* Probably a non-protein coding RNA
EVI2A 3752271          -1.56 0.024747* Ecotropic viral integration site 2A; protein involved in transmembrane signaling 
receptor receptor activity
NPM1 2840726 1.51 0.010982* Nucleophosmin; involved in ribosome biogenesis, protein chaperoning, histone 
assembly and many other functions with multiple binding partners
SZ vs NC: mOFC (area 11/12) right side only
CANX 2844385 1.48 0.006169** Calnexin; a chaperone protein involved in ensuring that only properly folded and 
assembled proteins proceed along the secretory pathway of endoplasmatic reticulum 
and Golgi apparatus
Table legend: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. #Genes under identifiers 3275252 and 3275388 are different splicing variants of the same GDI2 gene.
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development and are ubiquitously expressed 
in the brain, their involvement could also 
partly explain the pathological findings in the 
frontal and cingulate cortex, corpus callosum, 
and cerebellum in schizophrenia (Table 3). At 
the systems level, multiple neurotransmitter 
systems, including dopaminergic, 
glutamatergic and GABAergic can be affected 
through the dysfunction of these genes. For 
example, if the ACTR2-ACTR3 system of actin-
related proteins is disrupted, the result will 
be excessive pruning, with a loss of synaptic 
contact on pyramidal cells leading to an 
overactivation of long-range dopaminergic 
pathways [55, 56]. 
Following the trend of other cytoskeleton 
encoding genes such as ACTA2 and SEPT2, we 
show that the expression of KRT18 (keratin 18), 
as a member of the intermediate filament gene 
family, is significantly decreased in DLPFC and 
MOFC areas in subjects with schizophrenia. 
There has been one report about altered KRT17 
expression in lymphocytes of patients with 
schizophrenia [57] and overexpression of KRT18 
in rodent model of psychosis and patients with 
schizophrenia [46].
4.3. Genes associated with dopamine 
and glutamate signaling pathways
Calnexin is a chaperone molecule that facilitates 
protein folding and assembly, and may have 
a central role in sorting incorrectly folded 
proteins for degradation. Both differential 
splicing and de novo mutations [37] within the 
calnexin (CANX) gene have been associated 
with schizophrenia. Amongst others, it was 
shown that calnexin is involved in trafficking 
and expression of dopamine D1 and D2 [58], 
GABA-A [59] and AMPA glutamate receptors 
[60]. 
Our findings of differential expression of 
chromobox 3 (CBX3) and GDP dissociation 
inhibitor 2 (GDI2) provide additional evidence 
for the involvement of glutamate receptors 
in schizophrenia. CBX3 is involved in 
transcriptional silencing in heterochromatin-
like complexes, whereas GDI2 regulates the 
GDP-GTP exchange reaction of rab proteins, 
thus influencing membrane trafficking and 
vesicle formation. Kim et al. [43] have reported 
somatic deletions of CBX3 gene in the PFC and 
cerebellum of patients with schizophrenia. 
Treatment of rodents with N-methyl-D-
aspartate receptor (NMDAR) agonists has been 
an established animal model of schizophrenia 
(for review, see [61]) and these animals show 
aberrant expression of both CBX3 and GDI2. 
Furthermore, in vitro administration of MK-801, 
NMDAR antagonist, has been shown to increase 
GDI2 protein expression [39]. The increased 
expression of GDI2 observed in this study 
therefore could be the consequence of long-
term usage of antipsychotics by schizophrenic 
patients.
4.4. Genes associated with 
mitochondrial dysfunction
Mitochondrial dysfunction is another 
component of the etiology of schizophrenia 
thought to be involved in the abnormal 
neuronal function, plasticity, and brain circuitry 
that characterize the cognitive and behavioral 
symptoms of the disease. Additionally, there 
is evidence from rat models that a hyper-
dopaminergic state may have inhibitory effects 
on the mitochondrial complex 1 and 3 [62]. 
Sorting nexin 3 (SNX3) is involved in protein 
transport between cellular compartments 
and interacts with phosphatidylinositol-3-
phosphate [63]. Our finding of increased 
expression of SNX3 in the left hemisphere from 
DLPFC and MOFC of schizophrenic brains is in 
accordance with the study by Huang et al., who 
showed the same but in the superior temporal 
gyrus (area 22), and connecting this finding 
with mitochondria-associated genes and 
mitochondrial dysfunction in schizophrenia 
[38]. Importantly, other members of sorting 
nexin family have also been associated with 
schizophrenia, such as SNX2, SNX6, SNX8, SNX17, 
SNX19, SNX29, and SNX31 [64, 65].
As for SNX3, we found an increased 
expression of solute carrier family member 
25 member 3 gene (SLC25A3) in the MOFC of 
schizophrenia samples. The product of this 
gene catalyzes the transport of phosphate into 
the mitochondrial matrix. Other solute carrier 
family members have been also associated 
with the development of schizophrenia, such 
as SLC6A3 (dopamine transporter) [66] and 
SLC18A2 (vesicular monoamine transporter 
2) [66]. Interestingly, SLC25A3 interacts with 
CANX that is also differentially expressed in 
schizophrenia (see above). It has been reported 
that rare variants of SLC25A3 contribute to 
a higher risk of schizophrenia [41] and that 
carriers of SLC39A13 polymorphisms or novel 
mutations have global cognitive deficits, severe 
negative symptoms, and significantly more 
suicide attempts [67]. 
STARD7 (StAR related lipid transfer domain 
containing 7) acts as a lipid transporter in the 
transport of phosphatidylcholine between 
membranes [68]. We observed an increase in 
STARD7 expression in MOFC in our samples. 
Kim and Webster already reported a negative 
correlation of illness duration and STARD7 
expression in areas 8, 9, 10 and 46 [46]. A 
possible link of STARD7 and schizophrenia 
is through TCF4 (T cell-specific transcription 
factor 4), which activates its gene promotor (for 
a review, see [69]).
4.5. Genes associated with the cell-
cycle
Gene ontology analysis indicated that seven of 
the differentially expressed genes are involved 
in promoting the cell cycle: TARDBP, KRT18, 
SEPT2, SART3, ANAPC5, USP22 and NPM1. Here 
we will discuss the significance of ANAPC5 and 
USP22, and KAT7, as the other genes have been 
already discussed above. 
We show that ANAPC5 (anaphase promoting 
complex subunit 5), a component of anaphase 
promoting complex/cyclosome (APC/C) 
that is connected with centrosomes, was 
overexpressed in schizophrenia. Through its 
connection with the centrosome complex, 
ANAPC5 could interact with centrosome-
associated protein DISC1, a widely accepted 
schizophrenia risk-gene [42, 70]. 
USP22 (ubiquitin specific peptidase 22) is 
a histone-deubiquitinating component of a 
transcription regulatory histone acetylation 
complex, required for cell-cycle progression. 
We found an increased expression of USP22 in 
DLPFC in schizophrenia. This gene has been 
identified among top ranking gene sets as 
significantly enriched in schizophrenia [44] 
(Szatkiewicz et al., 2014). Moreover, a single 
nucleotide polymorphism found near the 
USP22 gene was associated with negative 
symptoms in schizophrenia [71]. 
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The expression of KAT7  (lysine 
acetyltransferase 7) was increased in DLPFC of 
schizophrenic brains. While the association of 
KAT7 with schizophrenia has not been described 
previously, bromodomain-containing protein 
1 (BRD1) – protein with which KAT7 forms a 
histone acetyltransferase (HAT) complex – has 
been implicated in schizophrenia, as well as in 
brain development [72-74]. 
4.6. Limitations of the study
The present study took care to match brains as 
closely as possible for age, an exclusive medical 
history of schizophrenia, and comparable post-
mortem delay so that confounding biases 
could be minimized. Nevertheless, other biases 
that could have contributed to influencing the 
results such as the specific pharmacological 
treatment regimen of each patient or the 
severity of pathological changes could not 
be accounted for.  We are aware that newer, 
increasingly recognized methods are now 
commonly used instead of RNA microarray, 
such as RNA sequencing. RNA sequencing 
has a higher signal-to-noise ratio than RNA 
microarray because it allows for the DNA to bind 
to specific regions of the genome, and does 
not have problems with cross-hybridization or 
non-ideal hybridization kinetics that are seen 
with RNA microarray [75, 76]. As described in 
details in the Materials and methods section, 
to accommodate for this disadvantage, 
the data were subjected to a procedure to 
minimize the background noise, as described 
by Irizarry et al. [20], and log2 transformation 
of yielded fluorescence intensities. Microarray 
is limited to detection of only transcripts of 
existing genomic sequencing, whereas RNA 
sequencing can also be used for discovering 
new transcripts. Moreover, RNA sequencing 
can quantify the transcripts with an absolute 
number value, rather than yielding a relative 
value as in microarray. Other research has 
suggested, even though relatively uncommon, 
that copy number variation (CNV) deletions 
or replications can lead to variable gene 
expression and cause schizophrenia with 
symptoms of differing severity [77, 78]. Thus, 
one of the limitations of our study is that, by 
using a RNA microarray, these CNV could not 
be detected. Additionally, the small sample size 
of six pathological brains in this study limits 
conclusions that can be made in relation to bias 
in the experimental design or the presence of 
CNV causing altered gene expression. Finally, 
in this study, we did not perform a statistical 
analysis to test for false positive results or 
determine the false discovery rate. Despite the 
small sample size, our P values, generally less 
than 0.01 confirm the high precision of the 
present data.
5. Conclusions
In this study we used Affymetrix microarray 
technology to perform a comprehensive 
transcriptome comparison of the cognitive 
regions of the frontal lobe, DLPFC and MOFC, 
from six clinically diagnosed schizophrenic 
brains and six control brains. Our analysis 
shows that the genes that exhibit differential 
expression have functions in RNA processing, 
nucleic acid metabolism, macromolecule 
metabolic processes, RNA splicing and cell 
cycle (Figure 3). Additionally, some of the 
other differentially expressed genes could be 
involved in abnormal brain development and 
activation of immunological mechanisms. 
Therefore, we compared our results with data 
from other studies regarding the expression 
of these genes. We gained valuable insights 
for further bioinformatics studies aiming at 
the detection of schizophrenia-associated 
molecular networks. Future studies should 
aim to validate these changes in larger 
cohorts of schizophrenic brains at gene and 
protein levels (including consideration of 
epigenetic and posttranslational changes). 
Also, as shown in the present study, additional 
comparisons of differential gene expression in 
the right and left hemispheres of the prefrontal 
cortex are required to help elucidate the 
mechanisms leading to decreased working 
memory, mentalization, and metacognition 
in schizophrenia. Bioinformatics and network 
pharmacology approaches could then be 
useful for identification of pharmacological 
compounds that may regulate these pathways.
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Appendix A. Supplementary data
Summary of gene expression data using 
the Affymetrix HG (human genome)-U133 
Plus 2.0 array. The MS Excel (.xls) table is 
formatted according to  Affymetrix hg18_
refseq_16_02_02_v2  protocol using the 
identical protocol and ID names for genes 
as GeneChip Human Exon 1.0ST Arrays 
(Affymetrix, Santa Clara, CA, USA).
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